We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Telix Pharmaceuticals is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $7.6 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $3.55 - $8.82 |
|---|---|
| 50-day moving average | $4.3016 |
| 200-day moving average | $5.9856 |
| Target price | $8.15 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.285 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$4.03
| 1 week (2022-06-03) | -1.47% |
|---|---|
| 1 month (2022-05-11) | 1.00% |
| 3 months (2022-03-11) | -17.59% |
| 6 months (2021-12-10) | -49.44% |
| 1 year (2021-06-11) | -19.40% |
|---|---|
| 2 years (2020-06-11) | 207.63% |
| 3 years (2019-06-11) | 315.46% |
| Revenue TTM | $7.6 million |
|---|---|
| Gross profit TTM | $5 million |
| Return on assets TTM | -37.95% |
| Return on equity TTM | -198.36% |
| Profit margin | 0% |
| Book value | 0.008 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $3.55 up to $8.82. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.2793. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Everything we know about the Bayrock Resources IPO, plus information on how to buy in.
Everything we know about the Critical Minerals Group IPO, plus information on how to buy in.
Everything we know about the Chalkos Metals Limited IPO, plus information on how to buy in.
Steps to owning and managing Cluey shares.
Steps to owning and managing Koba Resources shares.
Steps to owning and managing Rincon Resource shares.
Steps to owning and managing Payright shares.
Everything we know about the Iltani Resources IPO, plus information on how to buy in.
Bloom Impact Investing offers exclusively climate impact investing, with direct climate action being the goal.
Steps to owning and managing Kingfisher Mining shares.
